Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme that is implicated in suppressing T-cell immunity in normal and pathological settings. Here, we describe that spontaneous cytotoxic T-cell reactivity against IDO exists not only in cancer patients but also in healthy individuals. We show that the presence of such IDO-specific CD8 + T cells boosted T-cell immunity against viral or tumor-associated antigens by eliminating IDO + suppressive cells. This had profound effects on the balance between IL-17-producing CD4 + T cells and regulatory T cells.
Introduction
Induction of tolerance, which is a central mechanism counteracting tumor-specific immunity and preventing effective anti-cancer immune therapy, requires a specific environment in which tolerogenic dendritic cells (DC) play an essential role deviating the immune response away from effective immunity. It was recently shown that IDO provides a potential mechanism for the development of DC mediated T-cell tolerance. IDO + DC inhibit T-cell proliferation due to tryptophan depletion and accumulation of toxic tryptophan metabolites 1;2 . IDO + DC have been shown to induce T-cell anergy and/or generation of regulatory T cells (Tregs). In cancer patients, IDO elevation occurs in a subset of plasmacytoid DC in tumor-draining lymph nodes 3 . In addition, most human tumors overexpress IDO 4 . Activation of IDO in either tumor cells or nodal regulatory DC each appears to be sufficient to facilitate tumoral immune escape 2 . IDO may help tilting the tumor microenvironment from hostile to supportive for tumor cells, and also elaborate a peripheral mechanism of immune escape that could facilitate tumor progression 5;6 .
Tregs have been defined as a specialized subpopulation of T cells that act to suppress activation of the immune system and thereby maintain immune system homeostasis and tolerance to self-antigens 7;8 . Subsequently, they are additionally termed suppressor T cells. Tregs exist to down regulate immune responses in various inflammatory circumstances and ultimately assure peripheral T-cell tolerance. The best characterized subset of these immune suppressive cells are CD4 + CD25 high CD127 -Foxp3 + T cells [9] [10] [11] . Over the past years, additional regulatory T-cell subsets including CD8 + suppressor T cells have been described in humans and mice [12] [13] [14] . Recently, we identified very potent antigen-specific CD8 + suppressor T cells in PBMC from cancer patients 15 .
These natural occurring HLA-A2-restricted CD8 + T cells were specific for the anti-inflammatory molecule Heme Oxygenase-1 (HO-1). The data linked the cellular stress response to the regulation For personal use only. on April 21, 2017. by guest www.bloodjournal.org From of adaptive immunity and added a new dimension to the role of antigen-specific CD8 + T cells in the regulation of cellular immune responses.
We have recently described that IDO are spontaneously recognized by cytotoxic T cells (CTL) in cancer patients 16 . Thus, IDO-specific T cells were present in peripheral blood as well as in the tumor microenvironment. These IDO-reactive T cells were able to recognize and kill tumor cells, including directly isolated AML blasts, as well as IDO-expressing DC, i.e. one of the major immune suppressive cell populations. We could not detect spontaneous responses against IDO in the control group of healthy individuals. Thus, albeit IDO has an immune suppressive effect, the up regulation of IDO expression seems to induce a specific cytotoxic T-cell response. However, we found it quite astonishing that the T cells in the patients did not exhibit tolerance towards IDO, since IDO is inducible under normal physiological conditions. We speculated that this could suggest a more general role of IDO-specific T cells in the regulation of the immune system. IDO may play a critical role for the strength and duration of a given immune response due to its inflammation- 
Materials and methods

Donors
Peripheral Blood Mononuclear Cells (PBMC) were collected from healthy individuals and cancer patients (renal cell carcinoma, melanoma, and breast cancer). Blood samples from cancer patients were drawn a minimum of four weeks after termination of any kind of anti-cancer therapy. The majority of renal cell carcinoma patients had previously been treated with IL2 and IFN-α, most melanoma patients had received high dose IL2 and IFN-α, while all breast cancer patients were pretreated with several kinds of chemotherapy, (e.g. epirubicin, docetaxel, cabecitabine), trastuzumab, and/or endocrine therapy. Informed consent was obtained from the patients prior to any of these measures in accordance with the Declaration of Helsinki. All protocols were approved by the Herlev University Hospital ethics committee.
ELISPOT assay
The ELISPOT assay was used to quantify peptide-specific IFN-γ releasing effector cells as described previously 17;18 . The spots were counted using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers).
MHC-tetramer staining
PBMC were stained with PE coupled MHC-tetramers, followed by antibody staining with CD8-allophycocyanin (APC) and CD3-FITC (BD Biosciences). 7-Amino-Actinomycin D (7AAD) was used for exclusion of nonviable cells in all samples (BD Biosciences). MHC-tetramers were prepared as described 19;20 . (QVPLRPMTYK). The samples were analyzed and occasionally sorted on FACS Aria or FACS Canto II, using DIVA software (BD Biosciences).
Establishment of antigen-specific T-cell cultures and clones
PBMC were stimulated with irradiated (25 Gy), IDO5 ; ALLEIASCL)-loaded autologous DC with ß 2 m, IL-12 (PeproTech), and U/ml IL-7 (PeproTech) in X-vivo with 5% human AB serum. The cultures were restimulated every seven-ten days with IL-2. After four to five weeks, growing cultures were tested for specificity for IDO5 and specific cultures were cloned by limiting dilution in the presence of IDO5-loaded PBMC and IL-2. Growing clones were expanded with IL-2 and IDO5-loaded PBMC or Dynabeads CD3/CD28 T-cell expander (Dynal).
Cytotoxicity assay
Conventional 4 hour
51 Cr-release assays for CTL-mediated cytotoxicity was carried out as described elsewhere 21 . Target cells were peptide-loaded T2-cells, the colon cancer cell lines HCT116 and SW480 (ATCC), the melanoma cell line FM55M
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, in vitro generated autologous immature Dc (iDC) and matured DC (mDC), and allogeneic ex vivo isolated CD14 + monocytes (isolated using MACS CD14 + microbeads). In some assays, CD14 + monocytes were treated with 100 U/ml IFN-γ for two days prior to analysis. Lysis were blocked using the HLA class I specific mAb W6/32 (2 µg/100 µl).
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Down-regulation of IDO in cancer cells
For personal use only. on April 21, 2017. by guest www.bloodjournal.org From Human SW480 cancer cells were transfected with indicated short hairpin RNA (ShRNA) plasmids obtained from SuperArray using FuGene6 (Roche) according to manufacturers instructions. Blots were developed with the ECL system obtained from Amersham and a CCD camera (LAS-1000, Fujifilm). Antibodies used: anti-Cdk7 (MO-1) (Santa Cruz) and anti-IDO (Millipore Corporation).
Co-culturing with autologous IDO-specific T cells
PBMC were stimulated in vitro with 50 µg/ml viral peptide (CMV pp65 495-503 (NLVPMVATV), CMV IE1 316-324 (VLEETSVML) or Flu matrix p 58-66 (GILGFVFTL)). 40 U/ml IL-2 was added on day 2 and 6. The PBMC were either cultured alone or added autologous IDO5-specific T cells (in a PBMC to IDO5-specific T cell ratio of 2000:1) on day 6. On day 9, the cultures were stimulated with 120 U/ml IL-2. After 12 days in culture, the number of viral-specific T cells in the cultures, either cultured alone or added IDO5-specific T cells was compared by MHC-tetramer staining. The number of Tregs, IL-17A producing T cells and the CD4/CD8 cell ratio in the cultures were also compared. As a control, PBMC were co-cultured with autologous CD8 + T cells of irrelevant specificity.
Co-stimulation with IDO peptide
PBMC were stimulated in vitro with 25 µg/ml viral or tumor-associated antigens (CMV pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] (NLVPMVATV), CMV IE1 316-324 (VLEETSVML), or MART-1 26-35 (EAAGIGILTV)), either in coculture with 25 µg/ml IDO5 peptide or an irrelevant peptide (HIV-1 pol 476-484 (ILKEPVHGV)). 40 U/ml IL-2 was added every third day. Every seven days, the cultures were stimulated with a mixture of CMV-or MART-1 peptide plus IDO5 peptide, or a mixture of CMV or MART-1 peptide plus HIV-1 pol 476-484 peptide, respectively. Cells were stimulated with 10-, 100-, and 1000-fold diluted peptides for the second, third and fourth peptide stimulation, respectively. After three to four 
ELISA for quantitative determination of Tryptophan
Cell culture supernatants were collected and stored at -80°C. After precipitation and derivatization, Tryptophan concentrations were quantitatively determined by competitive ELISA according to manufactures instructions (Labor Diagnostika Nord). Quantification of unknown samples was achieved by comparing their absorbance with a reference curve prepared with known standards.
Induction of IDO-specific T cells by IFN-γ, CTLA4-Ig or CpG ODN
PBMC were stimulated with either100 U/ml IFN-γ, 1 ug/ml CpG ODN (Type B CpG oligodeoxynucleotide specific for human TLR9; InvivoGen) or 1 ug/ml cytotoxic T lymphocyte associated antigen 4 (CTLA4)-IgG2a fusion protein (Research Diagnostics) once a week. 40 U/ml IL-2 was added every third day. After four weeks, the cultures were tested for the presence of IDOspecific T cells by MHC-tetramer staining.
RNA preparation and reverse transcription-coupled PCR
Resulting cDNA was tested using primers for GAPDH (5′-AGGGGGGAGCCAAAAGGG-3′, 5′-GAGGAGTGGGTGTCGCTGTTG-3′, positions 440 and 980, respectively; product size 558 bp).
Primers suited for amplification were as follows: IDO (5′-TGTCCGTAAGGTCTTGCCAGG-3′; 5′-CGAAATGAGAACAAAACGTCC-3′, positions 408 and 557, respectively; product size, 170 bp).
Statistical analysis
The percentages of antigen-specific T cells between cultures were compared using one-tailed two 
Results
IDO5-specific T cells are detectable in healthy donors
First, we examined PBMC from healthy donors for the presence of T cells specific for the HLA-A2 restricted IDO-derived epitope IDO5 ; ALLEIASCL). We found that IDO-reactivity could readily be detected by IFN-γ ELISPOT and HLA-A2/IDO5 tetramer staining (Fig. 1A and B ).
All in all we examined 28 healthy donors for spontaneous T-cell reactivity against the HLA-A2 restricted IDO epitope and identified specific T cells in three individuals (Fig. 1A) . As a control of the HLA-A2/IDO5 tetramer, an IDO5-specific T-cell clone were stained (Fig. 1C ).
IDO5-specific T cells are specifically able to kill IDO-expressing cells
IDO-specific T-cell clones were established from bulk cultures by limiting dilution cloning from cancer patients 16 1I ).
IDO-specific T cells boost viral immunity
We utilized IDO-specific T-cell clones to examine a potential role of such cells in enhancing Importantly, these changes did not correspond to similar differences in the percentage of CD8 + and CD4 + T cells between the cultures (Fig. 2D ).
Likewise, we added IDO-specific T cells from a breast cancer patient to autologous PBMC cultures In one experiment the number of Flu-specific CD8 + T cells almost doubled from 7% to nearly 14% (Fig. 3A) . The addition of IDO-specific T cells at the same time decreased the amount of
+ Tregs in the cultures to the half (Fig. B) , while increasing the number of IL-17A producing CD4 + T cells from 0.2% to 0.6% (Fig. 3C) . Importantly, these changes did not correspond to similar differences in the percentage of CD8 + and CD4 + T cells between the cultures (Fig. 3D) . We additionally compared the activity of IDO between the cultures by measuring the amount of Tryptophan in the cell culture supernatants. Interestingly, the highest concentration of Tryptophan, i.e. least IDO activity, was found in cultures with added IDO-specific T cells (Fig. 3E ).
Addition of IDO-specific T cells additionally reduced the concentration of IL-10 in the cell culture supernatants, while increasing concentrations of IL-17A, IL-6 and TNFα as measured by standard cytokine ELISA (Fig 3F) . Notably, addition of autologous CD8 + T-cell clones of unknown specificities to PBMC from the same patient did not increase the number of tetramer positive, Fluspecific CD8 + T cells (data not shown). Likewise, we added a T-cell clone specific for the tumor- 
Co-stimulation with IDO peptide boosts T-cell reactivity against viral and tumor-associated antigens
To further analyze the supporting effect of IDO-specific T cells on T-cell responses, PBMC from 15
HLA-A2 + healthy donors and cancer patients were stimulated with an HLA-A2 restricted CMV or The increase in T-cell reactivity towards CMV-or MART-1 was calculated for each donor/patient as fold increase of MHC-tetramer-specific CD8 + T cells in co-culture with IDO5 peptide (Fig 4A) .
Notably, we observed from 1.5 to eight fold increases of tetramer-specific CD8 + T cells in 2/3 of the cultures with IDO-reactivity ( Fig 4A, B and C) . Importantly, co-stimulation with IDO5 peptide did not result in a decrease in CMV-or MART-1-reactivity in any of the examined individuals ( Fig.   4A ). Thus, co-activation of IDO-specific T cells not only boosted T-cell immunity towards viral antigens but also towards the well-known tumor-associated antigen MART-1.
Stimulation of IDO-specific T cells reduces Tregs numbers while boosting IL17 production
We examined the amount of Tregs and IL-17 producing CD4 + T cells in PBMC from melanoma patients stimulated with MART-1 peptide either in co-culture with IDO5 peptide or an irrelevant HIV-1 peptide in the presence of IL-2 as described above. We observed that activation of IDOspecific T cells with IDO5 peptide, not only boosted T-cell immunity towards MART-1 (Fig. 4A) concentrations of IL-17A, IL-6 and TNFα in the cell culture supernatants, whereas a lower amount of IL-10 was detected (Fig. 5F ). (Fig. 6E) . Thus, addition of HLA-A2/IDO5 tetramer positive T cells boosted T-cell immunity towards CMV antigens similar to the IDO-specific T-cell clones described above.
IDO-inducing agents stimulate IDO-specific T cells with supporter functions
For
Discussion
In the present study, we show that circulating IDO-specific, cytotoxic CD8 and other pro-inflammatory cytokines induces reprogramming of mature Tregs to acquire a phenotype resembling pro-inflammatory Th17 cells [38] [39] [40] . It has been shown that IDO play a vital 
